Verastem (VSTM) Earnings Date & Reports

Key Takeaways

• Verastem Oncology reported third quarter 2026 net product revenue of $24.0 million, up from $11.2 million in the prior-year quarter, but slightly below analyst expectations.
• GAAP (Generally Accepted Accounting Principles) net loss was $74.7 million, or $0.74 per share, compared with $98.5 million, or $1.35 per share, a year earlier.
• Non-GAAP adjusted net loss was $72.8 million, or $0.72 per share, wider than the roughly $0.44 loss-per-share consensus estimate.
• Research and development spending climbed 137% year over year to $68.8 million, driven by the VS-7375 pipeline and pivotal trial preparations.
• The company ended the quarter with $172.8 million in cash and investments, or about $422.8 million on a pro forma basis after an October offering.
• For additional context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Discover automated trading strategies and ideas through Trending AI Robots.

Earnings Context and Why It Matters

Verastem Oncology is a commercial-stage biopharmaceutical company focused on cancers driven by the RAS/MAPK signaling pathway. Its third quarter 2026 report matters because it measures two things at once: the continued commercial ramp of AVMAPKI FAKZYNJA CO-PACK, its first approved product for low-grade serous ovarian cancer (LGSOC), and the escalating investment in VS-7375, an oral KRAS G12D inhibitor the company views as a potential best-in-class asset. Investors are watching whether commercial revenue growth can keep pace with rising research costs, and whether clinical data readouts can justify a more aggressive pipeline build-out.

Reported Results

For the third quarter ended September 30, 2026, Verastem Oncology reported net product revenue of $24.0 million, up from $11.2 million in the same period a year earlier. The figure fell short of consensus estimates, which ranged from roughly $26 million to $26.8 million, as management described a more gradual sales ramp tied to the episodic nature of treatment persistence in a rare disease.

On a GAAP basis, the net loss was $74.7 million, or $0.74 per share, compared with a net loss of $98.5 million, or $1.35 per share, in the prior-year quarter. Non-GAAP adjusted net loss was $72.8 million, or $0.72 per share, versus $39.1 million, or $0.53 per share, a year ago. Both measures missed analyst expectations for a narrower loss.

Operating expenses totaled $99.2 million. Research and development costs rose 137% to $68.8 million, reflecting expanded clinical activity for VS-7375, while selling, general and administrative expenses increased 26% to $26.5 million. Management noted that VS-7375 delivered a 41% confirmed objective response rate (ORR) in previously treated pancreatic ductal adenocarcinoma (PDAC), including a 50% confirmed ORR in second-line patients.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following oncology and biotech names like Verastem, the AI Screener offers a structured way to identify comparable opportunities across the sector.

Market Reaction and Investor Sentiment

Reaction to the report centered on the revenue and bottom-line misses, with shares having added significantly year to date before the announcement. Sentiment remains divided: bulls point to the roughly doubled year-over-year product revenue, the strong refill dynamics supporting the CO-PACK launch, and the emerging VS-7375 clinical data, while bears focus on the steep rise in operating expenses and the wider-than-expected loss. The company's move to strengthen its balance sheet with a $250 million October offering signals both confidence in the pipeline and a willingness to fund costly pivotal development.

Forward Outlook and Key Factors to Monitor

Verastem's near-term narrative will be shaped by execution on two fronts. On the commercial side, investors should watch whether the CO-PACK revenue ramp accelerates as prescribers gain experience and as the new AVMAPKI tablet and blister pack formulation — which the FDA accepted for priority review with a decision expected by February 2027 — supports adherence and refills.

On the clinical side, the focus shifts to VS-7375. Following alignment with the FDA, the company plans to open its Phase 3 TARGET-D 301 trial in first-line KRAS G12D-driven metastatic pancreatic cancer by the end of 2026, with additional regulatory engagement planned on Phase 3 designs in colorectal and lung cancers.

Cost trends will remain a key monitor. The 137% increase in R&D spending reflects the burden of advancing multiple pivotal programs, and sustained investment could pressure the bottom line even as revenue grows. With pro forma cash of roughly $422.8 million and a stated runway into the first half of 2028, the company has flexibility, but investors will weigh the pace of spending against the cadence of data readouts and regulatory milestones.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations